Obexelimab, a therapy Zenas Biopharma is developing for a range of autoimmune diseases, almost completely prevented the formation of new inflammatory lesions in adults with relapsing forms of multiple sclerosis […] The post Obexelimab stops 95% of new MS brain lesions in trial appeared first on Multiple Sclerosis News Today.
